| ²é¿´: 111 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
edwardwtflľ³æ (ÕýʽдÊÖ)
|
[½»Á÷]
RaytideÊÇָʲô£¿
|
||
| ÔÚÉúÎïÀï |
» ²ÂÄãϲ»¶
ÖþÀÎÓªÑø°²È«ÏߣºÒÔ¾«×¼¼ì²â£¬»¤½¡¿µ»ùʯ
ÒѾÓÐ0È˻ظ´
ÍÆ¼öһЩ20ÖÖ°±»ùËá¼ì²âµÄʵ¼ÊÓ¦Óð¸Àý
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ51È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖеÄȤÊ£ºÊµÑéÆ÷²ÄµÄ ¡°ÎÚÁú¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖеÄȤÊ£ººÍʵÑé²ÄÁ쵀 ¡°¶·ÖǶ·Ó¡±
ÒѾÓÐ0È˻ظ´
µ°°×Öʼì²â£º¾«×¼·ÖÎö£¬½âËøÉúÎï·Ö×ÓµÄÃÜÂë
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´

dnaxxx
ÖÁ×ðľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 12 (СѧÉú)
- ½ð±Ò: 11074.2
- Ìû×Ó: 278
- ÔÚÏß: 351.1Сʱ
- ³æºÅ: 254121
- ×¢²á: 2006-05-27
- ÐÔ±ð: GG
- רҵ: ²¡¶¾¡¢²¡¶¾¸ÐȾÓëËÞÖ÷ÃâÒß
|
Raytide™ is a modified gastrin analog. There is one tyrosyl phosphorylation site per Raytide™ molecule. The carboxyl end of the peptide contains acidic and hydrophilic amino acid residues, while the amino terminus contains basic amino acids. In phosphoric acid the amino end is positively charged and binds to phosphocellulose paper (p81 Whatman). The distance between the two charged ends of the peptide prevents neutralization. Additionally, the peptide maintains an unfolded state and functions as an excellent substrate for protein-tyrosine kinases and tyrosine phosphatases (Nature 350, 359-62, 1991). Raytide™ EL, Cat. No. PK04, which has a higher labeling efficiency when used as either a kinase or a phosphatase substrate is also available. ¾ßÌågoogle¿´¹©Ó¦ÉÌÍøÕ¾ |
2Â¥2009-05-07 15:54:23
edwardwtfl
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 4197.9
- ºì»¨: 1
- Ìû×Ó: 705
- ÔÚÏß: 187Сʱ
- ³æºÅ: 631132
- ×¢²á: 2008-10-20
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö

3Â¥2009-05-07 18:46:56













»Ø¸´´ËÂ¥
